The present disclosure relates generally to unconjugated PLGA nanoparticles in the treatment of Alzheimer's Disease. The present disclosure provides a method of treating a subject having Alzheimer's Disease or a tauopathy or suspected of having Alzheimer's Disease or a tauopathy, the method includes administering a therapeutically effective amount of poly(D,L-lactide-co-glycolide) (PLGA) to the subject.

A composition including a poloxamer gel, wherein the poloxamer gel is a combination of poloxamer 407 and poloxamer 188, wherein the composition further include preserved water and wherein the composition does not contain pharmaceutical agents and radioactive compounds. A composition including a poloxamer gel, wherein the poloxamer gel is a combination of poloxamer 407 and poloxamer 188; wherein the composition further includes preserved water; wherein the composition is formed from poloxamer gel components having a mean size of at most 0.5 mm; and wherein the composition is a gel at temperatures ranging from 25.5° C. to 28.9° C. and a solid at temperatures ranging from 30° C. to 36° C.

A composition including a poloxamer gel, wherein the poloxamer gel is a combination of poloxamer 407 and poloxamer 188, wherein the composition further include preserved water and wherein the composition does not contain pharmaceutical agents and radioactive compounds. A composition including a poloxamer gel, wherein the poloxamer gel is a combination of poloxamer 407 and poloxamer 188; wherein the composition further includes preserved water; wherein the composition is formed from poloxamer gel components having a mean size of at most 0.5 mm; and wherein the composition is a gel at temperatures ranging from 25.5° C. to 28.9° C. and a solid at temperatures ranging from 30° C. to 36° C.

A new compound composition that is free of a side effect to a liver and used for alleviating the toxicity of an acetaminophen (APAP) medicament to the liver. The compound composition comprises (a) a pharmaceutically effective amount of acetaminophen and (b) a frequently-used safe and pharmaceutically acceptable excipient that can be combined with one or more than two medicaments that can reduce the toxicity of a drug via liver enzyme CYP2E1 metabolism to the liver. The compound is selected from the following group: Tween 20, microcrystalline cellulose, dicalcium phosphate, polyoxyethylene 23 lauryl ether, saccharin, mannitol, polyoxyethylene alkyl ether, sucralose, pyrrolidone, sodium starch glycolate, acrylic resin S100, carboxymethyl cellulose sodium, polyoxyethylene polyoxypropylene, menthol, low-substituted hydrocarbon propyl cellulose, pregelatinized starch, Dextrates NF hydrated, citric acid, polyoxyethylene castor oil, colloidal silica, polyethylene glycol monostearate aliphatic ester, sorbic acid, lemon oil, hydroxypropyl cellulose, sorbitol, acesulfame potassium, hypromellose phthalate, lactose monohydrate, maltodextrin, Brij 58, Brij 76, Tween 80, Tween 40, PEG 400, PEG 4000, PEG 2000, and the like, so as to reduce the side effect of the toxicity caused by acetaminophen to the liver.

A new compound composition that is free of a side effect to a liver and used for alleviating the toxicity of an acetaminophen (APAP) medicament to the liver. The compound composition comprises (a) a pharmaceutically effective amount of acetaminophen and (b) a frequently-used safe and pharmaceutically acceptable excipient that can be combined with one or more than two medicaments that can reduce the toxicity of a drug via liver enzyme CYP2E1 metabolism to the liver. The compound is selected from the following group: Tween 20, microcrystalline cellulose, dicalcium phosphate, polyoxyethylene 23 lauryl ether, saccharin, mannitol, polyoxyethylene alkyl ether, sucralose, pyrrolidone, sodium starch glycolate, acrylic resin S100, carboxymethyl cellulose sodium, polyoxyethylene polyoxypropylene, menthol, low-substituted hydrocarbon propyl cellulose, pregelatinized starch, Dextrates NF hydrated, citric acid, polyoxyethylene castor oil, colloidal silica, polyethylene glycol monostearate aliphatic ester, sorbic acid, lemon oil, hydroxypropyl cellulose, sorbitol, acesulfame potassium, hypromellose phthalate, lactose monohydrate, maltodextrin, Brij 58, Brij 76, Tween 80, Tween 40, PEG 400, PEG 4000, PEG 2000, and the like, so as to reduce the side effect of the toxicity caused by acetaminophen to the liver.

A new compound composition that is free of a side effect to a liver and used for alleviating the toxicity of an acetaminophen (APAP) medicament to the liver. The compound composition comprises (a) a pharmaceutically effective amount of acetaminophen and (b) a frequently-used safe and pharmaceutically acceptable excipient that can be combined with one or more than two medicaments that can reduce the toxicity of a drug via liver enzyme CYP2E1 metabolism to the liver. The compound is selected from the following group: Tween 20, microcrystalline cellulose, dicalcium phosphate, polyoxyethylene 23 lauryl ether, saccharin, mannitol, polyoxyethylene alkyl ether, sucralose, pyrrolidone, sodium starch glycolate, acrylic resin S100, carboxymethyl cellulose sodium, polyoxyethylene polyoxypropylene, menthol, low-substituted hydrocarbon propyl cellulose, pregelatinized starch, Dextrates NF hydrated, citric acid, polyoxyethylene castor oil, colloidal silica, polyethylene glycol monostearate aliphatic ester, sorbic acid, lemon oil, hydroxypropyl cellulose, sorbitol, acesulfame potassium, hypromellose phthalate, lactose monohydrate, maltodextrin, Brij 58, Brij 76, Tween 80, Tween 40, PEG 400, PEG 4000, PEG 2000, and the like, so as to reduce the side effect of the toxicity caused by acetaminophen to the liver.

A population of polymeric particles for controlled release of therapeutic agents which have unacceptable toxicity when administered intravitreally can be safely administered suprachoroidally at the same intravitreal concentration or dose. In a preferred embodiment, the particles have a high loading of the agent and is released without a substantial initial burst release. Examples demonstrate safety and efficacy of delivery of acriflavine-containing particles when administered suprachoroidally. The examples demonstrate sustained release with low to no burst release of the highly water soluble agent for up to 60 days.

A population of polymeric particles for controlled release of therapeutic agents which have unacceptable toxicity when administered intravitreally can be safely administered suprachoroidally at the same intravitreal concentration or dose. In a preferred embodiment, the particles have a high loading of the agent and is released without a substantial initial burst release. Examples demonstrate safety and efficacy of delivery of acriflavine-containing particles when administered suprachoroidally. The examples demonstrate sustained release with low to no burst release of the highly water soluble agent for up to 60 days.

The present invention features animal feed comprising an effective amount of carotenoid-oxygen copolymer for use in methods for: (i) ameliorating one or more symptoms of subclinical mastitis; (ii) reducing the frequency of subclinical mastitis progressing to full clinical mastitis; (iii) reducing bacteria count in colostrum or milk of a mammal; (iv) reducing physiological stress of a mammal; (v) improving reproductive performance of a mammal; and/or (vi) improving the health of offspring of a mammal. The invention also features a method for producing pasteurized milk from a mammal which has been fed the animal feed supplemented with carotenoid-oxygen copolymer.

Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same.